Aspirin in Diabetes

• Research type

  Research Study

• Full title

  Modulation of Clot Structure and Platelet Function by Aspirin in Individuals with Diabetes: The Role of Aspirin Dose and Glycaemic Control

• IRAS ID

  12359

• Contact name

  Penny Rice

• Sponsor organisation

  University of Leeds

• Eudract number

  2008-007875-26

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  Diabetes is associated with increased risk of vascular disease, including heart attack and strokes. People with diabetes also have a worse short and long term prognosis following a heart attack with a higher death rate, when compared to non-diabetics. Aspirin is used for both primary and secondary prevention of cardiovascular events. It inhibits platelet function and has a direct effect on the structure of blood clots and fibrinolysis. Despite its proven clinical effect in the non-diabetic population, recent evidence suggests it is less effective in people with diabetes. This makes the use of aspirin in people with diabetes questionable, particularly because it is associated with increased gastrointestinal bleeding. This study will aim to clarify how people with diabetes respond to aspirin and look for possible reasons why aspirin is less effective. This will be done by analysing blood clot structure, fibrinolysis and platelet function in people with diabetes with and without treatment with aspirin and comparing this to a control group of subjects without diabetes.

• REC name

  Yorkshire & The Humber - Leeds West Research Ethics Committee

• REC reference

  09/H1307/12

• Date of REC Opinion

  1 Apr 2009

• REC opinion

  Further Information Favourable Opinion